Related Experiment Video
Updated: Aug 13, 2025
06:22
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
713
Experimental Approaches to Diabetes Mellitus
Muhammed Yayla1, Damla Binnetoğlu1
1Department of Pharmacology, Kafkas University Faculty of Medicine, Kars, Turkey.
The Eurasian Journal of Medicine
|January 19, 2023
Summary
This review details current experimental diabetes models, covering in vivo and in vitro methods for studying diabetes and developing new treatments. It analyzes the advantages and disadvantages of these crucial research tools.
Area of Science:
- Endocrinology
- Pharmacology
- Biomedical Research
Background:
- Diabetes mellitus is a prevalent chronic disease characterized by hyperglycemia.
- Developing effective diabetes treatments requires robust experimental models.
- Current models vary in methodology, timing, and applicability to diabetes types.
Purpose of the Study:
- To comprehensively review existing experimental diabetes models.
- To present the methodologies, advantages, and disadvantages of each model.
- To provide insights for selecting appropriate models in diabetes research.
Main Methods:
- Literature review of in vivo and in vitro experimental diabetes models.
- Analysis of protocols for inducing diabetes in experimental settings.
- Comparative assessment of model characteristics and outcomes.
Main Results:
- Various experimental models can simulate type 1 and type 2 diabetes.
- Models differ significantly in their development timelines and influencing factors.
- Each model presents unique benefits and limitations for research.
Conclusions:
- Experimental diabetes models are essential for advancing diabetes understanding and therapy.
- Careful consideration of model methodology, pros, and cons is vital for research success.
- This review offers a guide to the current landscape of diabetes model systems.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
327
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
327
01:22Diabetes Mellitus: Overview and Type I Subtype
2.9K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.9K
01:20Pathophysiology of Diabetes
1.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.1K
01:22Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
01:24Glucagon-like Receptor Agonists
383
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
383
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
256
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
256